November 5th, 2012
Reclassifying AHA on the West Coast
Amit Shah, MD, MSCR
An evening epidemiology session highlights the value of AHA.12, as a fellow garners multiple insights from a series of speakers.
November 5th, 2012
AHA 2012 Headquarters
CardioExchange Editors, Staff
CardioExchange is dedicated to bringing you the latest from AHA 2012 and it can all be found right here.
November 4th, 2012
NIH Trial Gives Surprising Boost to Chelation Therapy
Larry Husten, PHD
The TACT trial finds that cardiovascular endpoints were lower with chelation therapy than placebo in patients with prior MI, but trial investigators and others have expressed considerable caution about the proper interpretation of the results.
November 4th, 2012
AHA with Some Perspective
Reva Balakrishnan, MD, MPH
A fellow from NYU looks at the AHA through the lens of last year’s conference and her institution’s recent experience with Hurricane Sandy
November 4th, 2012
ARCTIC Blows a Cold Wind on Platelet Function Tests
Larry Husten, PHD
The use of platelet-function tests to monitor and guide antiplatelet therapy in PCI patients has sparked heated debate. Cardiologists have sought to reconcile biological plausibility with the absence of clinical evidence. Now the ARCTIC (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy versus a Monitoring-guided Strategy for Drug-Eluting Stent Implantation versus Continuation One […]
November 4th, 2012
Management of Aortic Stenosis: Up Close and in Person
Megan Coylewright, MD MPH
An AHA.12 session on management of aortic stenosis includes an impressive line-up of experts and underscores the value of attending the meeting.
November 4th, 2012
The Benefits of Technology
Eiman Jahangir, MD
Dr. Eiman Jahangir sorts through the AHA schedule in minutes using their mobile app and wonders why the AHA still bothers printing the full program booklet. Do you think there should be a way to opt out of receiving the whole schedule on paper?
November 2nd, 2012
FDA Investigation Finds No Excess Bleeding Risk for Dabigatran
Larry Husten, PHD
In its latest assessment of a highly controversial issue, the FDA has found no indication that bleeding rates for dabigatran (Pradaxa, Boehringer-Ingelheim) are any higher than the bleeding rates for warfarin. The FDA investigation was in response to the large number of post-marketing reports of bleeding in people taking dabigatran. Click here to for the full FDA […]
October 30th, 2012
Ablation for Treatment-Naive A-Fib Patients?
CardioExchange Editors, Staff
Younger, healthier treatment-naive patients with a-fib can be offered initial ablation therapy, although drug therapy remains the default, according to the authors of this recent study in the NEJM.
October 29th, 2012
Selections from Richard Lehman’s Literature Review: October 29th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include CV risk factors and peripheral artery disease in men, radiofrequency ablation in paroxysmal AF, CPR duration and survival after in-hospital cardiac arrest, an everolimus-eluting stent vs. a bare-metal stent in STEMI, job strain and CHD, and more.
NEJM Journal Watch — Recent Cardiology Articles- Oral Semaglutide Approved to Lower Cardiovascular Risk in High-Risk Patients with Type 2 Diabetes
- Covid-19 Vaccines Improve Heart Outcomes
- Detecting Atrial Fibrillation After Transient In-Hospital Episodes
- Cardiac Involvement with Mycoplasma pneumonia: More Common Than Previously Thought
- Amyloid in the Heart